Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001038097 | SCV001201544 | pathogenic | Ataxia-telangiectasia syndrome | 2019-03-18 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. Loss-of-function variants in ATM are known to be pathogenic (PMID: 23807571, 25614872). This variant has been observed in an individual affected with ataxia-telangiectasia (PMID: 10817650). This variant is not present in population databases (ExAC no frequency). This sequence change creates a premature translational stop signal (p.Leu1775*) in the ATM gene. It is expected to result in an absent or disrupted protein product. |
Ambry Genetics | RCV004031058 | SCV005017903 | pathogenic | Hereditary cancer-predisposing syndrome | 2023-11-17 | criteria provided, single submitter | clinical testing | The c.5324delT pathogenic mutation, located in coding exon 35 of the ATM gene, results from a deletion of one nucleotide at nucleotide position 5324, causing a translational frameshift with a predicted alternate stop codon (p.L1775*). This variant has been observed in individual(s) with ataxia-telangiectasia (Li A et al. Am J Med Genet, 2000 May;92:170-7). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |
Myriad Genetics, |
RCV004789374 | SCV005405952 | pathogenic | Familial cancer of breast | 2024-09-18 | criteria provided, single submitter | clinical testing | This variant is considered pathogenic. This variant creates a termination codon and is predicted to result in premature protein truncation. |